Value Of Pre-IDE Meetings Debated; FDA To Explore Impact On PMAs
This article was originally published in The Gray Sheet
Executive Summary
Planned improvements to submission tracking capabilities will enable FDA to investigate industry queries concerning the impact of pre-IDE meetings on premarket review